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Abstract
The GABAB receptor agonist baclofen has been studied extensively in preclinical models of 
alcohol use disorders, yet results on its efficacy have been uncertain. Racemic baclofen, which is 
used clinically, can be broken down into separate enantiomers of the drug. Baclofen has been 
shown to produce enantioselective effects in behavioral assays including those modeling reflexive 
and sexual behavior. The current studies sought to characterize the enantioselective effects of 
baclofen in two separate models of ethanol consumption. The first was a Drinking-in-the-Dark 
procedure that provides “binge-like” ethanol access to mice by restricting access to a two hour 
period, three hours into the dark cycle. The second was a two-bottle choice procedure that utilized 
selectively bred High Alcohol Preferring 1 (HAP1) mice to model chronic ethanol access. HAP1 
mice are selectively bred to consume pharmacologically relevant amounts of ethanol in a 24-hour 
two-bottle choice paradigm. The results showed that baclofen yields enantioselective effects on 
ethanol intake in both models, and that these effects are bidirectional. Total ethanol intake was 
decreased by R(+)- baclofen, while total intake was increased by S(-)-baclofen in the binge-like 
and chronic drinking models. Whereas overall binge-like saccharin intake was significantly 
reduced by R(+)- baclofen, chronic intake was not significantly altered. S(-)- baclofen did not 
significantly alter saccharin intake. Neither enantiomer significantly affected locomotion during 
binge-like reinforcer consumption. Collectively, these results demonstrate that baclofen produces 
enantioselective effects on ethanol consumption. More importantly, the modulation of 
consumption is bidirectional. The opposing enantioselective effects may explain some of the 
variance seen in published baclofen literature.
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Introduction
We have previously demonstrated that systemic administration of the GABAB receptor 
agonist baclofen increased ethanol drinking in C57BL/6J (B6) mice using the limited-access 
ethanol drinking procedure Drinking in the Dark (DID) (Moore et al., 2007). However, 
varied response to baclofen is common in the general ethanol intake and self-administration 
literature. Whereas baclofen decreases responding and amount of self-administered ethanol 
in operant paradigms (Besheer, Lepoutre, & Hodge, 2004; Janak & Michael Gill, 2003; 
Maccioni et al., 2012; Walker & Koob, 2007), reduces breakpoint to obtain ethanol 
(Maccioni et al., 2008), and decreases ethanol intake (Colombo et al., 2000; Colombo et al., 
2003; Stromberg, 2004), baclofen administration has also been shown to increase ethanol 
intake (Czachowski, Legg, & Stansfield, 2006; Petry, 1997; Smith, Boyle, & Amit, 1999). 
Thus, although GABAB receptors appear to have a clear role in the modulation of ethanol 
intake-related behavior, the nature of this role remains uncertain.
A potential explanation for the variance seen in the baclofen literature is the composition of 
racemic baclofen. The absolute configurations R- and S- baclofen comprise the racemate, 
with the R(+)- enantiomer being the more potent of the two (Falch et al., 1986; Witczuk, 
Khaunina, & Kupryszewski, 1980). Experiments examining R- and S- baclofen separately 
have shown that R-is more effective than S- at moderating sexual behavior, motor 
movements, locomotion, spinal cord segmental inhibition, reflexes, and blood pressure 
(Fromm, Shibuya, Nakata, & Terrence, 1990; Olpe et al., 1978; Paredes & Agmo, 1989). 
The activity ratio of R:S varies between behavioral assays, making it important to consider 
enantioselective aspects of drug action when considering therapeutic uses of the drug 
(Jamali, Mehvar, & Pasutto, 1989).
The initial goal of the current studies was to evaluate whether baclofen has enantioselective 
effects on limited-access ethanol intake in B6 mice using the DID procedure. DID is a 
binge-like model of ethanol intake that produces pharmacologically relevant levels of 
consumption in a two-hour period (Rhodes, Best, Belknap, Finn, & Crabbe, 2005; Rhodes et 
al., 2007). Mice consume considerable amounts of ethanol with blood ethanol 
concentrations (BECs) exceeding 100 mg/dl. Since its development, DID has been widely 
used to test a broad range of pharmacological targets for alcohol use disorders (AUDs) 
(Gupta et al., 2008; Hendrickson, Zhao-Shea, & Tapper, 2009; Kamdar et al., 2007; Moore 
et al., 2007; Sparta et al., 2008).
Our second goal for the current studies was to explore the pharmacological mechanisms 
behind chronic ethanol intake by separately assessing if these drugs also worked to modulate 
two-bottle choice intake in High Alcohol Preferring (HAP) selectively bred mice. HAP mice 
were selectively bred in three replicates for high intake of 10% ethanol solution in a 24 hour 
free-choice drinking paradigm (Grahame, Li, & Lumeng, 1999; Oberlin, Best, Matson, 
Henderson, & Grahame, 2011). Line 1 (HAP1) mice, which are the furthest along in the 
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selection process, were used in the current experiments. These mice represent a model of 
excessive chronic ethanol intake, displaying ethanol consumption of over 20 g/kg/day. 
Examination of drinking rhythms in these mice have demonstrated that intake in HAP1 mice 
occurs at a rate of 1.5 g/kg/hour immediately following lights off and is sustained 
throughout the 12-hour dark period, with HAP1 mice reaching average BECs over 200 
mg/dl eight hours into the dark cycle (Matson & Grahame, 2011). Little testing for 
pharmacological AUD treatments has been carried out in this model of chronic ethanol 
intake. O'Tousa et al. (2013) showed that triple monoamine reuptake inhibitors reduced 
binge-like and chronic drinking, while the GABAA α1 receptor subunit preferring drug 3-
propoxy-β-carboline hydrochloride (3-PBC) reduced binge-like drinking in line 2 and 3 
HAP mice. The ability of 3-PBC to reduce chronic drinking was not assessed.
We initiated the current studies in B6 and HAP1 mice with two general hypotheses. The first 
of these was that the R(+)- baclofen enantiomer would reduce total ethanol intake in both 
paradigms. Based on baclofen effects seen in the first hour of drinking by Moore et al. 
(2007), we also hypothesized that these effects would be time-dependent. Our second 
hypothesis was that the S(-)- baclofen enantiomer would not affect ethanol intake in either 
drinking paradigm, based on its minimal efficacy in other behavioral assays (Paredes & 
Agmo, 1989).
Method
Animals
For all DID studies, male B6 mice were purchased from The Jackson Laboratory (Bar 
Harbor, ME). Mice were delivered at 7 weeks of age and were allowed two weeks to 
acclimate to the reverse light cycle before testing started. For all two-bottle choice studies, 
HAP1 male and female animals from the 47th, 51st and 53rd generations were obtained from 
Dr. Nicholas Grahame at IUPUI. All animals were single housed 7 days prior to onset of 
testing, and between 9 and 10 weeks of age at onset of testing. Lights were maintained on a 
12-hr reverse light-dark schedule with lights out at 8, 9, or 11am. Animals had access to 
food and water at all times, apart from during DID ethanol presentation when water was not 
available. All procedures were approved by the IUPUI School of Science Institutional 
Animal Care and Use Committee and conformed to the Guide for the Care and Use of 
Laboratory Animals (The National Academic Press, 2003).
Drugs
Ethanol (195 proof) was obtained from Pharmco, Inc. (Brookefield, CT). Ethanol solutions 
(10% v/v and 20% v/v) were made using tap water. Saccharin was obtained from Sigma 
Aldrich (St. Louis, MO) and was dissolved in a 0.32% w/v solution using tap water. R(+)- 
and S(-)- baclofen were obtained from Sigma Aldrich (St. Louis, MO) and dissolved in 0.9% 
saline to concentrations of 0, 1, 3, and 10 mg/kg for R(+)- studies and 0, 1, 3, 10, and 30 
mg/kg for S(-)- studies. All solutions were delivered via intraperitoneal injections in a 
volume of 0.1ml per 10 g of body weight.
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Method
Drinking-in-the-Dark—Male B6 mice were used in the DID studies. DID was slightly 
modified from that of Rhodes et al. (2005) and Moore et al. (2007). Briefly, each day 3 
hours into the dark cycle, animals were provided daily access to a 20% ethanol or 0.32% 
saccharin solution for two hours. Ethanol was presented in 10ml graduated plastic tubes. 
Water was not available during the two hours of ethanol access. Days 1-3 constituted an 
acquisition phase, with total 2hr fluid intake volumes recorded each day. On Day 4 all 
animals received a saline injection immediately prior to 2hr ethanol access. On Day 5 
animals received a drug injection (drugs and doses described below) immediately prior to 
2hr ethanol access. Animals were matched to drug groups based on Day 4 ethanol 
consumption. Fluid intakes were recorded at the 1hr and 2hr time intervals on Days 4 and 5. 
Blood samples were taken on Day 5 immediately following 2hr access for determination of 
BECs (see Retro-orbital sinus blood section).
Two-bottle choice drinking—HAP1 mice were used in the two-bottle choice studies. 
Both male and female mice were included in these studies due to the limited availability of 
animals. Mice received two weeks of drinking acquisition which closely followed methods 
described by Oberlin et al. (2011) and Matson and Grahame (2011). Briefly, 25ml graduated 
glass cylinders were filled with 10% v/v ethanol or distilled water. One ethanol and one 
water bottle were placed on each cage at all times during the acquisition phase. Volumes 
were recorded every other day immediately prior to lights off. Bottles were only removed to 
replace ethanol or water with fresh fluid when fluid levels were less than 10mL or if the 
fluid had not been changed within the past four days. To assess drug effects on alternative 
reinforcers, all studies were also run using identical methodology, but with 0.32% saccharin 
in place of 10% ethanol.
HAP mice consume low levels of ethanol during the light part of the light/dark cycle but 
ramp up drinking at lights-off and sustain a high level of drinking throughout the entire dark 
period (Matson & Grahame, 2011). We therefore chose to inject drug immediately at lights 
off. On Day 15 all animals received a saline injection to habituate them to the injection 
procedure. On Day 16 animals received a drug injection (drug and doses described below) 
immediately prior to lights out. Consumption on Days 15 & 16 was recorded at 1, 2, and 3 
hours post-injection. On the test days, ethanol or saccharin was removed one hour prior to 
injection to assure ethanol clearance and reintroduced immediately following injection using 
10mL graduated bottles. This was the only time animals went without ethanol or saccharin. 
In each experiment, Day 16 drug doses were assigned by matching animals to groups based 
on total consumption following the Day 15 saline injection. Retro-orbital sinus blood 
samples were taken from ethanol consuming animals immediately after the end of the 
drinking period on drug test days for determination of BECs (see Retro-orbital sinus blood 
section).
R(+)- baclofen DID—Thirty-nine male B6 mice were used in the R(+)- baclofen DID 
dose-response study. On Day 5 animals received a 0, 1, 3, or 10 mg/kg dose of R(+)- 
baclofen. These doses were chosen based on previously published literature which found 
both increases and decreases in drinking at each separate dose (Czachowski et al., 2006; 
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Moore et al., 2007). B6 mice were first tested for baclofen effects on ethanol intake. The 
same animals were subsequently used to test effects of baclofen on saccharin intake 
following a two week water-drinking wash-out period.
S(-)- baclofen DID—One hundred thirteen male B6 mice were included in the S(-)- 
baclofen DID dose-response study. On Day 5 animals received a 0, 1, 3, 10, or 30 mg/kg 
dose of S(-)- baclofen. As for R(+)-, these doses were chosen based on previous literature 
(Czachowski et al., 2006; Moore et al., 2007). The higher 30 mg/kg dose was also included 
because S(-)- baclofen has been shown to be less potent than R(+)- baclofen (Falch et al., 
1986; Witczuk et al., 1980). We included the larger dose to capture a broader range of 
effects on ethanol intake. Sixty-five of these animals were used to test the effects of baclofen 
on ethanol intake, while the other 50 were used to assess the effects of baclofen on saccharin 
intake.
Baclofen and free choice drinking—Twenty eight HAP1 mice (12 male, 16 female) 
were included to assess the effects of R(+)- and S(-)- baclofen on two-bottle choice drinking. 
Due to limited animal availability, only the doses that were effective in moderating drinking 
in B6 mice were used so that a similar between-subjects design could be employed. On Day 
16 animals received a saline (0 mg/kg), 10 mg/kg S(-)-, or 10 mg/kg R(+)- baclofen dose. 
Following a one-week water drinking wash-out period, the ability of each baclofen 
enantiomer to modulate saccharin intake was tested in the same animals. Mice did not 
necessarily receive the same dose of baclofen twice, as dose groups were determined by 
matching intake following the Day 15 saline injection.
Locomotor activity—Forty-six B6 males were included in a study to characterize the 
locomotor effects of R(+)- and S(-)- baclofen during access to 20% ethanol or 0.32% 
saccharin during DID. However, these animals were not naïve. The 23 animals that received 
ethanol had previous 7 day DID experience with 2% sucrose, but were ethanol naïve. The 23 
animals that received saccharin had previous 7 day DID experience with 20% ethanol, but 
were saccharin naïve. All animals had received one dose of the adenosine A2A antagonist 
MSX-3 or the A1 antagonist DPCPX three or more weeks before locomotor testing. Animals 
were matched to drug treatment group based on baseline consumption, previous drug 
exposure, and previous dose exposure. The same 5 day DID paradigm as described in the 
DID method section was used. On Day 5, animals received a 10 mg/kg dose of R(+)- or 
S(-)- baclofen. The control groups received a saline injection of equal fluid volume titrated 
to their body weight. The 10 mg/kg doses of R(+)- and S(-)- baclofen were chosen because 
they were known to have an effect on ethanol consumption. To reduce animal usage, only 
the doses shown to have an effect on drinking were used to characterize locomotor activity.
Locomotor activity was recorded using Opto M3 13“x9” Mouse Cages (Columbus 
Instruments, Columbus, OH). The animal's cage is placed directly into the monitor and 
locomotor scores determined based on sensor beam breaks. Each cage monitor was started 
immediately following introduction of ethanol or saccharin each day. Locomotor scores 
were collected in 5 minute bins during the two hours of reinforcer access.
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Retro-orbital sinus blood sampling
Retro-orbital sinus blood samples were collected using 50 μl microcapillary tubes (Fisher 
Science, Pittsburgh, PA) immediately after the final ethanol drinking session for each 
experiment. Samples were centrifuged and plasma was decanted and stored at −80 °C until 
the time of BEC determination. An Analox Alcohol Analyzer (Analox Instruments, 
Lunenburg, MA) was used to determine blood ethanol content.
Statistical Analysis
Data were analyzed using IBM SPSS version 20 (Armonk, NY). For all studies, acquisition 
data were analyzed using a repeated measures ANOVA with day as the within-subjects 
variable. Tukey's post-hoc tests were used when appropriate for the acquisition data. For 
analysis of baclofen's effects on DID drinking, Day 5 total intake, 1hr intake, 2hr intake, and 
BEC data were analyzed by one-way ANOVAs with dose as the between-subjects factor. 
One way ANOVAs at each hour were used in favor of a Time*Dose repeated measures 
ANOVA to match the 1 hour analysis used by Moore et al. (2007). Dunnett's post-hoc tests 
were used when appropriate with the 0 mg/kg group set as the control.
Locomotor activity was analyzed using a repeated measures Day*Compound*Time Bin 
ANOVA with compound as the between-subjects factor and day (saline versus drug) and 
five minute time bins as the within-subjects factors.
Analyses of the two-bottle choice data included the 0 mg/kg control, 10 mg/kg R(+)-, and 10 
mg/kg S(-)- baclofen doses. Sex was initially included as a factor in all analyses; however 
the omnibus ANOVA indicated no main or interactive effects of sex on intake. Therefore 
data were collapsed on this factor. An omnibus Time*Dose repeated measures ANOVA 
with time as the within-subjects factor and dose as a between subjects factor was used to 
analyze ethanol and saccharin intake, as well as respective water intake. Ethanol and 
saccharin preference were analyzed using a one-way ANOVA with Dose as the between 
groups factor. Preference was calculated by dividing the amount of ethanol or saccharin 
consumed by total fluid consumed. BECs for the ethanol animals were compared using a 
one-way ANOVA with dose as the between subjects factor. Dunnett's post-hoc tests were 
used when appropriate with 0 mg/kg set as the control. For DID and two-bottle choice tests, 
bivariate correlations were run between total test day intake and BECs for ethanol 
experiments. Significance was set at p < .05 for all overall tests and was corrected for all 
necessary post-hoc tests.
Results
DID in B6 mice and R(+)- baclofen: Ethanol
Acquisition of ethanol intake is shown in Fig. 1A. The analysis revealed that intake was 
stable across days 1-4; F(3,158) = 1.03, p > .05. A significant effect of R(+)-dose on Day 5 
total intake was revealed; F(3,38) = 4.546, p < .01, where the 10 mg/kg dose of R(+)- 
baclofen reduced ethanol intake compared to the 0 mg/kg group (p < .05) (Fig. 1B). 
ANOVAs analyzing the individual hourly intake revealed that this effect was specific to the 
first hour of intake; F(3,38) = 3.855, p < .05. There was no significant effect of dose in the 
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second hour of intake (p > .05) (Fig. 1C). R(+)- baclofen also had a significant effect on 
BECs; F(3,38) = 3.870, p < .05. The 10 mg/kg dose of baclofen significantly reduced BECs 
compared to the 0 mg/kg group (p < .05) (Fig. 1D). BECs were strongly correlated with total 
2 hour ethanol intake; r(39) = .922, p < .001 (data not shown).
DID in B6 mice and R(+)- baclofen: Saccharin
Acquisition of saccharin intake is shown in Fig. 1A. There was a significant main effect of 
day; F(3,158) = 11.93, p < .05, with consumption on Day 3 being higher than consumption 
on Day 1. There was a significant effect of dose on Day 5 total intake; F(3,38) = 5.51, p < .
01, with the 10 mg/kg dose reducing total saccharin intake compared to the 0 mg/kg group 
(Fig. 1E). The dose effect was not specific to hour; ANOVAs analyzing consumption at 
each hour revealed significant dose effects on intake (p's < .05). Dunnett's post-hoc tests 
revealed that the 10 mg/kg dose reduced intake at both hours (p's < .05) (Fig. 1F).
DID in B6 mice and S(-)- baclofen: Ethanol
Acquisition of ethanol intake is shown in Fig. 2A. There was a main effect of day; F(3,186) 
= 3.90, p < .05, with consumption being lower on Day 4 than on Days 2 and 3. A significant 
effect of S(-)- baclofen dose on Day 5 total intake was revealed; F(4,62) = 2.54, p < .05. 
Dunnett's post-hoc tests revealed that the 10 mg/kg dose increased drinking compared to the 
0 mg/kg group (p < .05) (Fig. 2B). ANOVAs analyzing the hourly intake revealed that this 
effect was specific to the second hour of intake; F(4,62) = 7.029, p < .001. Dunnett's post-
hoc tests revealed that both the 3 and 10 mg/kg doses increased drinking in the second hour 
compared to the 0 mg/kg group (p's < .05) (Fig. 2C). There was no significant effect of dose 
on the first hour of intake (p > .05). A one-way ANOVA revealed no dose effect on BEC; 
F(4,39) < 1, p > .05 (Fig. 2D). There was a strong, significant correlation between total 
intake and BEC; r(63) = 0.763 (data not shown).
DID in B6 mice and S(-)- baclofen: Saccharin
Acquisition of saccharin consumption is shown in Fig. 2A. There was a main effect of day; 
F(3,199) = 9.52, p < .05, with consumption being higher on Day 4 than on Days 1 and 3. 
There were no significant dose effects of S(-)- baclofen on total saccharin intake; F(4,49) = .
916, p > .05 (Fig. 2E). Further, there were no significant dose effects observed during either 
hourly reading (p's > .05) (Fig. 2F).
Two-bottle choice in HAP1 mice and R(+)- and S(-)- baclofen: Ethanol
During acquisition, HAP1 mice reached levels of drinking previously seen by Matson & 
Grahame (2011) (Fig. 3A). There was a main effect of day; F(13,312) = 3.52, p < .01, and a 
linear contrast pattern with intake increasing over days (p < .01). Sex was initially included 
as a factor, but was found to be insignificant in all analyses and was therefore removed from 
all subsequent analyses. Day 16 dose groups were matched for total 3-hour consumption on 
Day 15. Mean ± Standard Error (SEM) ethanol consumption for each group on Day 15 was 
5.90 ± 0.19 g/kg, 5.67 ± 0.36 g/kg and 5.04 ± 0.44 g/kg for the control, S(-)-, and R(+)- 
baclofen groups, respectively. For Day 16 drinking, the omnibus Dose*Time ANOVA 
revealed a main effect of both dose and time (p's < .05). Dunnett's post hoc test revealed that 
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total ethanol intake was reduced in the R(+)- 10 mg/kg group, but increased in the S(-)- 10 
mg/kg group compared to the 0 mg/kg group (p's < .05) (Fig. 3B). Within-subjects contrast 
effects showed both linear and quadratic effects of time (p's < .05), with consumption at 
hours 2 and 3 being lower than hour 1, and the lowest consumption occurring during hour 2 
(Fig. 3C). There was no overall interaction of Time*Dose; F(4,48) = 2.16, p = .087. 
However, one-way ANOVAs were run at each time-point to match the analyses used for the 
binge-like intake. There was a significant effect of dose at each time point, with S(-)- 
baclofen increasing intake at hour 3 (p < .05) and trending towards increasing intake at hour 
1 (p = .056) compared to the control group. R(+)- baclofen reduced ethanol intake at hours 2 
and 3 compared to the control groups (p's < .05). A one-way ANOVA revealed a significant 
effect of dose on BEC (p < .05). Dunnett's post hoc tests revealed that the R(+)- 10 mg/kg 
dose significantly reduced BEC compared to the 0 mg/kg dose (p < .05), whereas the S(-)- 
10 mg/kg dose trended towards increasing BEC compared to the 0 mg/kg dose (p = .057) 
(Fig. 3D). Total ethanol intake and BEC were strongly and significantly correlated; r(27) = 
0.985, p < .01 (data not shown).
The effects of R(+)- and S(-)- baclofen on water intake and ethanol preference were also 
examined. The Dose*Time ANOVA analyzing water consumption revealed no main effects 
or interaction of dose and time (p's > .05). Mean ± SEM water intakes for the groups were 0 
mg/kg = 5.35 ± 2.66 ml, S(-)- 10 mg/kg = 3.60 ± 0.70 ml, R(+)- 10 mg/kg = 1.27 ± 0.56 ml. 
The one way ANOVA analyzing ethanol preference on the test day revealed a strong trend 
towards a dose effect (p = .05). However, Dunnett's post hoc tests revealed that neither drug 
dose was different from the 0 mg/kg control (p's > .05). The mean ± SEM ethanol 
preferences for each dose group were 0 mg/kg = 93.10 ± 4.18%, S(-)- 10 mg/kg = 96.94 ± 
0.62%, and R(+)- 10 mg/kg = 84.92 ± 3.59%.
Two-bottle choice in HAP1 mice and R(+)- and S(-)- baclofen: Saccharin
HAP1 mice reached levels of saccharin consumption previously reported by Oberlin et al. 
(2011) during the acquisition phase (Fig. 4A). There was no effect of day during the 
acquisition phase; F(13, 351) = 1.55, p > .05. Sex was initially included as a factor, but was 
found to be insignificant in all analyses and was therefore removed. Total mean ± SEM 
saccharin intake on Day 15 was 146.49 ± 35.35 ml/kg, 155.18 ± 24.71 ml/kg, and 130. 14 ± 
28.74 ml/kg for the control, S(-)-, and R(+)- baclofen groups, respectively. On Day 16, the 
omnibus Dose*Time ANOVA showed a main effect of dose on consumption; F(2,25) = 
6.02, p < .05. However, Dunnett's post hoc test revealed that neither drug dose was 
significantly different from the 0 mg/kg control group (Fig. 4B). The main effect of time did 
not reach significance; F(2,50) = 2.92, p = .063. There was no interaction of time*dose; 
F(4,50) = 1.70, p > .05 (Fig. 4C). One way ANOVAs at each time point showed a 
significant effect of dose at hours 1 and 2 (p's < .05). However, neither R(+)- or S(-)- 
baclofen were significantly different from the control group at those time-points.
The effects of R(+)- and S(-)- baclofen on water consumption and saccharin preference were 
also examined. An omnibus Dose*Time ANOVA revealed no significant effects or 
interaction of dose and time on water intake (p's > .05). Total mean ± SEM water intakes for 
each group were 0 mg/kg = 12.74 ± 4.47 ml, S(-)- 10 mg/kg = 22.0 ± 12.54 ml, R(+)- 10 
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mg/kg = 6.84 ± 4.22 ml. A one-way ANOVA analyzing the effect of dose on saccharin 
preference revealed no significant effects (p > .05). Mean ± SEM saccharin preference for 
each group were 0 mg/kg = 91.11 ± 3.0%, S(-)- 10 mg/kg = 88.32 ± 6.25%, R(+)- 10 mg/kg 
= 90.55 ± 3.84%.
Home-cage locomotor activity during DID
Acquisition of ethanol intake was stable across days (p > .05). Total mean ± SEM intakes 
for Days 1-4 were 2.33 ± 0.30, 2.65 ± 1.22, 2.40 ± 0.35, and 2.71 ± 0.32 g/kg, respectively. 
The effect of R(+)- and S(-)- baclofen on 2hr ethanol intake is shown in Table 1. There was 
a significant effect of baclofen compound on Day 5 total 2 hour ethanol intake; F(2,22) = 
11.67, p < .01. Dunnett's post-hoc tests revealed that total 2 hour drinking was lower in the 
group that received R(+)- baclofen compared to the saline group. There was a significant 
effect of compound for each hour of drinking independently (p's < .05). Dunnett's post-hoc 
tests revealed that at hour 1, neither baclofen group was significantly different from the 
saline group. At hour 2, the S(-)- baclofen group consumed more than the saline group (p < .
05).
Acquisition of saccharin intake was stable across days (p > .05). Total mean ± SEM intakes 
for Days 1-4 were 70.28 ± 7.34, 82.48 ± 12.31, 74.97 ± 9.10, and 75.45 ± 8.43 ml/kg, 
respectively. The effect of R(+)- and S(-)- baclofen on 2hr saccharin intake is shown in 
Table 1. There was a strong trend towards an effect of baclofen on total 2 hour intake; 
F(2,22) = 3.42, p = .053. This effect was driven by decreased total drinking in the R(+)- 
group. There was also an effect of baclofen on the first hour of drinking; F(2,22) = 4.88, p 
< .05, with R(+)- baclofen reducing drinking compared to saline. There were no significant 
main effects of baclofen compound on intake in hour 2 (p < .05).
The corresponding locomotor activity data are shown in Figure 5. A repeated measures 
Day*Compound*Time Bin ANOVA analyzing the locomotor scores of animals that 
received access to ethanol revealed a significant main effect of Day, with total locomotion 
being lower on day 5 (the drug day) (p < .05). There was also a main effect of Time, but no 
other significant main effects or interactions (Figs. 5A, 5B). A repeated measures 
Day*Compound*Time Bin ANOVA revealed the same pattern of results for the animals that 
received access to saccharin. There was only a main effect of Day, with locomotion being 
lower on the drug day, and a main effect of Time Bin (Figs. 5C, 5D).
Discussion
The current studies highlight the enantioselective effects of baclofen in a binge-like and 
chronic model of ethanol drinking. In both models, a 10 mg/kg dose of R(+)- baclofen 
reduced total ethanol intake, whereas a 10 mg/kg dose of S(-)- baclofen increased total 
ethanol intake. R(+)- baclofen significantly reduced binge-like saccharin intake in the DID 
model, but not saccharin intake in the free-choice model. As seen in Figure 4, the 10 mg/kg 
R(+)- baclofen dose appears to reduce saccharin consumption compared to the control group 
in the first and second hour of drinking, however there were no significant differences on 
total or hourly drinking between groups. S(-)- baclofen did not significantly alter saccharin 
intake in either test. Furthermore, while high levels of drinking and pharmacologically 
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relevant BECs have been reported in HAP mice (Matson & Grahame, 2011; Oberlin et al., 
2011), this study demonstrates that BECs in HAP mice correlate strongly with ethanol 
intake, and that corresponding intake is amenable to pharmacological intervention. The 
current study also elucidates some of the neurobiological underpinnings of drinking in HAP 
mice by confirming that chronic ethanol consumption in HAP1 mice can be modulated via 
administration of baclofen.
Although only male B6 mice were used in the DID studies, both male and female HAP1 
mice were used in the two-bottle choice studies. Sex was initially included as a factor in all 
statistical analyses for the HAP1 studies, but it was not found to be a significant variable in 
any analysis and was therefore removed. However, sex is known to play an important role in 
ethanol consumption. Female HAP mice have been previously shown to consume more 
ethanol than their male counterparts during 24-hour free-choice drinking sessions (Matson & 
Grahame, 2011), and estrous cycle is known to modify the amount of ethanol consumed, the 
pattern of consumption, and the pharmacodynamics of ethanol (Ford, Eldridge, & Samson, 
2002; Robinson, Brunner, & Gonzales, 2002). Although estrous status affects ethanol 
consumption, the opposite is also true. Female rats exposed to 12 days of 4 or 8 g/kg of 
intragastric ethanol entered a stage of disrupted estrous cycling, spending more time in 
diestrous (Eskay, Ryback, Goldman, & Majchrowicz, 1981). This same disruption has been 
observed in rats fed a liquid ethanol diet for an extended period of time (Emanuele, 
LaPaglia, Steiner, Kirsteins, & Emanuele, 2001; Sanchis, Esquifino, & Guerri, 1985). As 
female mice in the current study received 16 days total of ethanol access and consistently 
consumed over 20 g/kg of ethanol per day, it is likely that many of them entered a period of 
disrupted estrous cycling. As many of the female mice were likely in the diestrous phase at 
the time of drug testing, variability in the female drinking due to estrous status would have 
been greatly reduced. However, we cannot directly speak to estrous status or how it affected 
consumption in female mice, as estrous stage was not monitored in the present study.
In the B6 mice, effects on ethanol consumption were time-dependent. R(+)- baclofen 
reduced consumption in the first hour of access, whereas S(-)- baclofen increased 
consumption in the second hour of access. This late increase in consumption may explain 
why S(-)- baclofen failed to alter BECs following binge-like ethanol access. Our lab has 
previously demonstrated that S(-)- baclofen increases ethanol consumption in the second 
hour of drinking, but does not increase BECs following site-specific administration into the 
nucleus accumbens shell (Kasten & Boehm, 2014). As ethanol consumption readings were 
taken after a fairly large one hour intake window, it is possible that animals consumed most 
of that ethanol at the end of the drinking session and that it had not been fully absorbed at 
the point of BEC determination, which was two hours after bottles on. The differences 
observed following administration of S(-)- baclofen are likely not the result of leak, as 
bottles were tested daily for leak. Moreover, we employ the use of empty cages with bottles 
on them for the sole purpose of controlling for random leak. Animals were caged on the 
same rack within the animal room, meaning any existing leak should have occurred at a 
similar rate in all cages. Although there was a trend towards a significant increase in BEC in 
the HAP1 mice following an injection of 10 mg/kg S(-)- baclofen it did not reach 
significance. The HAP1 mice showed a biphasic pattern in drinking following S(-)- baclofen 
administration, with a trend towards an increase in the first hour of consumption and a 
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significant increase in the 3rd hour of consumption. This late increase in drinking without 
significantly increased in BECs also supports the BEC data for the B6 animals.
R(+)- and S(-)- baclofen have been shown to alter a multitude of behaviors and 
physiological constructs, including sexual, motor and locomotor, reflexes, and spinal cord 
and segmental inhibition (Fromm et al., 1990; Olpe et al., 1978; Paredes & Agmo, 1989). 
All of these measures have shown relative resistance to the S-enantiomer. Conversely, our 
experiments demonstrate that S(-)- baclofen is not only significantly active in altering binge-
like and free-choice ethanol intake, but that it does so in a manner opposite that of the R(+)-
enantiomer. These results may explain some of the variance that has been observed in the 
baclofen literature on intake and self-administration using the racemic mixture.
A possible source of the differing actions of the two baclofen enantiomers may relate to 
where and how they bind in the brain. Binding of baclofen is dependent on the absolute 
configuration and the molecular rotation of the molecule. The absolute configurations of d- 
and l-baclofen (S- and R-, respectively), are equally efficacious at displacing GABA in low- 
and high-affinity membranes, but are much less efficacious at the high-affinity sites 
(Waddington & Cross, 1980). However, the (-) molecular rotation and GABA are equally 
able to displace racemic baclofen in low-affinity membranes, whereas the (+) molecular 
rotation displaces racemic baclofen to a much lesser extent (Bowery, Hill, & Hudson, 1983). 
Both (-)baclofen and R-baclofen have been shown to bind selectively in the cerebellum and 
hippocampus, respectively, with (-)baclofen binding to (-) selective sites (Drew, Johnston, & 
Weatherby, 1984; Haas, Greene, & Olpe, 1985). Our lab has begun work aimed at 
determining whether the enantiomers of baclofen are working in a brain region-specific 
manner. For example, we demonstrated that R(+)- and S(-)- baclofen bidirectionally alters 
ethanol, but not saccharin, intake following direct injection into the nucleus accumbens shell 
(Kasten & Boehm, 2014). Other brain regions of interest would include those involved in 
reinforcement, such as the nucleus accumbens core, ventral pallidum, ventral tegmental area, 
and prefrontal cortex. There may also be differences with how these molecules interact with 
other neurotransmitters. The (-) baclofen isomer interacts with norepinephrine whereas R-
baclofen may be responsible for other non-GABAergic effects of baclofen (Karbon, Duman, 
& Enna, 1984; Waddington & Cross, 1980). Individual differences in populations of 
GABAB receptors may increase or decrease the efficacy of racemic baclofen in reducing 
ethanol intake in preclinical models and in treating AUDs clinically.
One concern that surrounds interpretation of baclofen studies is how the drug affects 
locomotion. Cryan et al. (2004) have demonstrated that open-field locomotor activity is 
reduced in ethanol naïve animals following one hour pretreatment with a 10 mg/kg dose of 
R- baclofen. To characterize how the potential sedative effects of baclofen may be 
interfering with the ability to consume the reinforcer, we used a home-cage locomotor 
activity apparatus to quantify activity during drinking. Our results provide strong evidence 
that sedative effects of baclofen are not responsible for the changes in drinking observed. 
Locomotor activity was not altered by the 10 mg/kg doses of R(+)- or S(-)- baclofen, the 
same doses that decrease or increase drinking, respectively. The accompanying consumption 
data showed the same general pattern of intake as observed in the drinking-only studies; 
whereas R(+)- baclofen reduced total ethanol and hour 1 saccharin intake, S(-)- baclofen 
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increased ethanol intake in the second hour but did not significantly increase total intake. A 
secondary concern includes potential effects of the compounds on water consumption. 
While there were no significant drug effects on water consumption in the free-choice 
drinking studies, it is important to consider that water intake was highly variable. Although 
no outliers were identified, some of the animals consumed much more water than others. 
This range in consumption contributed to high variability which may have decreased the 
ability to identify an existing drug effect on water intake.
In conclusion, these studies demonstrate differential stereospecific actions of baclofen on 
ethanol consumption in models of excessive ethanol consumption. These studies are the first 
to establish that baclofen acts in a stereospecific and bidirectional manner on ethanol 
consumption, and that the reductions in drinking are not due to sedative effects. The effects 
of S(-)- baclofen are important considering the variable response observed using racemic 
baclofen clinically and pre-clinically. Susceptibility to one enantiomer over another in 
clinical and pre-clinical populations may influence response to the drug and drug 
effectiveness, also potentially explaining differences in the previous literature. Overall, these 
results show that GABAB receptors play a role in moderating excessive ethanol 
consumption, that modulation of ethanol consumption is stereospecific, and that GABAB 
receptors continue to be a viable target for development of novel therapeutic treatments for 
AUDs.
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• R(+)- baclofen reduces ethanol intake.
• S(-)- baclofen increases ethanol intake.
• Pharmacological characterization of High Alcohol Preferring Line 1 mice.
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Figure 1. R(+)- baclofen reduces binge-like reinforcer intake
A) Acquisition of ethanol and saccharin intake. B) The R(+)- baclofen enantiomer reduced 
total binge-like ethanol intake in B6 mice at the 10 mg/kg dose. C) The effect on intake was 
specific to the first hour of consumption. D) The 10 mg/kg R(+)- dose also reduced BECs. 
E) Total binge-like saccharin intake was also reduced at the 10 mg/kg R(+)- baclofen dose. 
F) This result was significant at both hours. Means ± SEM are depicted. Asterisk (*) 
indicates different than 0 mg/kg at p < .05. Double asterisk (**) indicates different than 0 
mg/kg at p < .01. Group n's = 9-10.
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Figure 2. S(-)- baclofen increases binge-like ethanol intake
A) Acquisition of ethanol and saccharin intake. B) The S(-)- baclofen enantiomer increased 
total binge-like ethanol intake in B6 mice at the 10 mg/kg dose. C) The effect on intake was 
specific to the second hour of consumption, with the 3 mg/kg and 10 mg/kg dose increasing 
intake. D) Dose effects on intakes were not reflected in BECs. E) S(-)- baclofen did not alter 
total saccharin intake. F) S(-)-baclofen did not alter hourly saccharin intake. Mean ± SEM is 
depicted. Asterisk (*) indicates different than 0 mg/kg at p < .05. Group n's for panels A-C = 
12-13. Group n's for panel D and E = 10.
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Figure 3. The separate baclofen enantiomers bidirectionally modulated free-choice ethanol 
intake in HAP1 mice
A) Acquisition of 24-hour access daily ethanol intake. B) Total 3 hour intake on the drug 
day indicates that R(+)- baclofen reduced ethanol intake whereas S(-)-baclofen increased 
drug intake compared to a saline injection. C) One-way ANOVAs at each of the three 
testing hours revealed dose effects at each hour of consumption. D) BEC following ethanol 
intake was reduced in the R(+)- baclofen group and trended towards an increase in the S(-)- 
baclofen group compared to control. Mean ± SEM is depicted. Asterisk (*) indicates 
different than 0 mg/kg at p < .05. Double asterisk (**) indicates different than 0 mg/kg p < .
01. Pound sign (#) indicates a trend of p < .06 compared to 0 mg/kg. Group n's = 9-10.
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Figure 4. The separate baclofen enantiomers did not significantly modulate free-choice saccharin 
intake in HAP1 mice
A) Acquisition of 24-hour access daily saccharin intake. B) Total 3 hour intake following 
the drug injection. Neither drug group was significantly different from the control group. C) 
Hourly intake for each of the three testing hours following the drug injection showed no 
significant effects. Mean ± SEM is depicted. Group n's = 9-10.
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Figure 5. The separate baclofen enantiomers did not alter home-cage locomotion in B6 mice
A) Home-cage locomotor scores of ethanol drinking animals on Day 4 following a saline 
injection. B) Home-cage locomotor scores of ethanol drinking animals on Day 5 following 
drug injection. C) Home-cage locomotor scores of saccharin drinking animals on Day 4 
following saline injection. D) Home-cage locomotor scores of saccharin drinking animals on 
Day 5 following drug injections. For both reinforcers, there was a main effect of day and 
time. Locomotion was lower in both groups on Day 5 (panels B and D). Mean ± SEM is 
depicted. Group n's = 7-8.
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